Additionally, the following conditions may warrant careful consideration based on clinical judgment, though evidence specifically linking these conditions to increased risk with tirzepatide is limited: History of significant gastrointestinal motility disorders that could be exacerbated by further slowing of gastric emptying Inflammatory bowel disease with active inflammation or history of stricturing complications Recent abdominal surgery , particularly procedures involving the gastrointestinal tract Severe chronic constipation that is difficult to manage Regarding pancreatitis, the FDA label advises clinicians to consider alternative antidiabetic therapy in patients with a history of pancreatitis, as GLP-1 receptor agonists have been associated with acute pancreatitis in some cases
Lee SJ, Sanchez-Watts G, Krieger JP, Pignalosa A, Norell PN, Cortella A, et al
Maxiliv Injection Therapy Area Gastrointestinal 1.0 Generic name Glutathione for injection 600 mg/via 2.0 Quantitative and qualitative composition Each vial contains : Glutathione BP 600 mg Excipients q.s
Data availability Details of the search strategy and list of identified articles can be found at Footnotes This article is being simultaneously published in Diabetologia (10.1007/s00125-022-05787-2) and Diabetes Care (10.2337/dci22-0034) by the European Association for the Study of Diabetes and American Diabetes Association
The drugs also show promise for treating liver disease and Alzheimers disease